Our Evolution

In response to the continued increase in demand for lentiviral and retroviral GMP services, Genezen officially completed construction on an additional 25,000 square feet of faciility space including additional process development, analytical development and quality control labs as well as GMP cell banking and GMP manufacturing suites within its Fishers Innovation Center. The latest phase of the expansion was officially opened by Indiana’s Governor Eric Holcomb and Fishers Mayor Scott Fadness.

Comprised of experienced industry experts, Genezen’s Scientific Advisory Board (SAB) was created to esnure continued focus on the company’s core value of leading with science while staying in line with best practices and innovating as the field advances. The SAB’s initial members included: Chris Ballas, SVP of Manufacturing for Innovative Cellular Theraputics; Spencer Hoover, trained virologist and former Director of Process and Analytical Development at CCRM; and Kai Lipinski, Chief Scientific Officer at Vibalogics.

After kicking off construction earlier in the year, Genezen officially opened its lentiviral and retroviral process development and analytical lab in Fishers, Indiana, featuring the most up-to-date technology available. This completed the first phase of the multi-phase plan for Genezen’s 75,000+ square foot facility.

Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector invests in Genezen.

Expansion of our process development lab begins. Due to complete in Fall 2021, the lab is the first part of our new 25,000 square foot cGMP-compliant lentiviral vector production facility which will also offer a full suite of analytical capabilities, ready in early 2022.
It’s the first phase of a broader master plan for a 75,000+ square foot facility.

Creating nearly 100 high-wage jobs, we announced plans to open a research and development lab and clean manufacturing facility with office space in the Crosspoint Business Park in the growing life-science hub Fishers, IN.

Following an incredible revenue growth from 2017 to 2019 of 424%, the Indiana Business Journal has named Genezen Laboratories the fastest growing company in central Indiana.

The laboratory excels in cell manufacturing for clinical trials. The partnership initially enabled the production of GMP grade retroviral and lentiviral vectors with quality control testing including vector titer by functional assay FACS or PCR, mycoplasma, and sterility testing.

Genezen set out to connect academia and pharma and began working closely with Dr. Ken Cornetta at Indiana University, who has more than 25 years of experience in viral vector production and testing. His vision of making vector production readily available informs our work today. As our clients’ needs grew, we added the expertise of Indiana University, a pioneer in many therapies with who we still partner today to expand our clinical trial sample testing capabilities.